Literature DB >> 10199589

Prevalence of glutamic acid decarboxylase antibodies amongst young Malaysian diabetics.

W M Wan Nazaimoon1, I Faridah, M Singaraveloo, I S Ismail, W B Wan Mohamad, R Letchuman, R Rasat, R Pendek, F L Hew, I H Sheriff, B A Khalid.   

Abstract

This study determined the prevalence of glutamic acid decarboxylase antibodies (GAD Ab) in a group of 926 young Malaysian diabetics of three ethnic groups, Malay, Chinese, and Indian. Patients were clinically diagnosed to be Type 1 or Type 2 before the age of 40 years. The overall GAD Ab positivity was 17.4% (161/926), significantly higher in the Type 1 than the Type 2 diabetics (35.5%, 116/329 vs. 7.5%, 45/597, P=0.0001). Compared to GAD Ab negative patients, seropositive diabetics were diagnosed at younger age (21.2+/-0.9 vs. 27.4+/-0.3 y, P=0.0001), had lower fasting (289+/-27.4 vs. 640+/-17.6 pmol/l, P=0.0001) and post-glucagon C-peptide levels (527+/-51.8 vs. 1030+/-28.9 pmol/l, P=0.0001). There were no racial differences in the prevalence of GAD Ab; of the total Type 1, 30.8, 36.4, and 39.4% were Malay, Chinese, and Indian diabetics, respectively and of the total Type 2, 8.8, 8.2, and 4.4% were Malay, Chinese, and Indian diabetics respectively. There was a curvilinear relationship between GAD Ab and the post-glucagon C-peptide levels, suggesting that GAD Ab do play a role in the beta-cells destruction and could be an important immune marker for the LADA group. This study reconfirmed previous reports that the autoimmune mechanisms in the Type 1 Asian diabetics are indeed different from the Caucasians, and further investigations should be carried out to explain the differences.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10199589     DOI: 10.1016/s0168-8227(98)00108-9

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  1 in total

1.  Challenges in the classification and management of Asian youth-onset diabetes mellitus- lessons learned from a single centre study.

Authors:  Toh Peng Yeow; Evelyn Su-Yin Aun; Chee Peng Hor; Shueh Lin Lim; Chong Hui Khaw; Nor Azizah Aziz
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.